RxDoctor Payments Data

Subbarao Mylavarapu, MD

Cardiovascular Disease · Newport Beach, CANPI 1659330850

Payments from drug & device makers

$292,781in general payments, 2019–2025

Across 553 payments — averaging $529.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$103K
  • Edwards Lifesciences$100K
  • Microvention, Inc.$62K
  • Shockwave Medical, Inc$7K
  • Siemens Medical Solutions USA, Inc.$5K
  • Cordis US CORP.$4K
  • plus $12K from 48 others
$5,125in research payments, 2019–2025

Across 2 payments — averaging $2562.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Microvention, Inc.$5K

What the payments were for

  • Consulting fees$151,68975%
  • Speaking & faculty fees$33,17016%
  • Travel & lodging$4,0902%
  • Food & beverage$13,4027%
  • Education$1750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$292,781 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$798,589
Medicare patients
1,775
Services billed
5,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$341,170
XareltoRivaroxaban262$316,217
EntrestoSacubitril/Valsartan88$116,008
JardianceEmpagliflozin51$64,905
FarxigaDapagliflozin Propanediol36$37,718
Repatha SureclickEvolocumab26$27,821
Praluent PenAlirocumab20$19,383
Repatha PushtronexEvolocumab15$17,836
BrilintaTicagrelor20$16,791
Repatha SyringeEvolocumab16$12,681
NexletolBempedoic Acid11$8,400
Amiodarone Hcl85$6,192
Atorvastatin Calcium438$4,431
Potassium Chloride79$4,263
Prasugrel Hcl31$4,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$566$341,170260 claims
Johnson & JohnsonXarelto$462$316,217262 claims
NovartisEntresto$818$116,00888 claims
Boehringer IngelheimJardiance$410$64,90551 claims
AstraZenecaFarxiga, Brilinta$211$54,51056 claims
Esperion Therapeutics, Inc.Nexletol$59$8,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →